News

Under the agreement, Arrowhead will receive research funding and could be eligible for development, regulatory and commercialization milestone payments of approximately $32.8m for each development candidate, an additional

The additional data had shown that Epi proColon was able to demonstrate 61% sensitivity for 23 cases in stages 0 and 1 , 75% for 16 cases in

Under the collaboration, Encubator will develop the business together with Chalmers School of Entrepreneurship while Stora Enso will generate new ideas. Stora Enso renewable packaging executive vice president

In the DiP technology, transfer RNA (tRNA) are extracted, purified, fluorescently labeled, and introduced into the cells to be monitored, claims the company. tRNAs, which form part of

Cell culture media are growth substances and nutrients for cells or microorganisms, required in every biopharmaceutical manufacturing process. As part of the agreement, SSB will sell and market

The supplemental new drug application (sNDA) submitted to the FDA adds the company’s goal of expanding the Vascepa manufacturing supply chain. Amarin chairman and chief executive officer Joseph

The company, based at Stevenage Bioscience Catalyst, UK, raised £11.5m in Series A financing to advance the molecules into clinical studies. Funding will primarily be focused on the

The collaboration, planned for three years, will leverage GlycoVaxyn’s bio-conjugation technology in developing vaccines against a range of undisclosed bacterial pathogens. GlycoVaxyn co-founder and chief scientific officer Michael

The mobile application enables clients to search the company’s more than 1000 bioanalytical assays from an iPhone, iPad, or Android Smartphone. PharmaNet/i3 business development executive director Farah Ahmad